My biotech business journal watch - year 2002 [ this week | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 ]

 Can't find the biotech business article published in 2002? 
Try a Google search!
Google

  1. Fox JL. Surprise US election results may boost biotech. Nat Biotechnol. 2002 Dec;20(12):1176. [PubMed]
  2. Thomas SM, Hopkins MM, Brady M. Shares in the human genome-the future of patenting DNA. Nat Biotechnol. 2002 Dec;20(12):1185-8. [PubMed]
  3. Rzucidlo EC, Nassif CL. Patent opportunities in bioinformatics. Drug Discov Today. 2002 Nov 1;7(21):1081-2. [PubMed]
  4. Brower V. When will the bear move on?: The current problems of the biotechnology industry are not solely a reflection of the whole market but are also caused by some specific problems. EMBO Rep. 2002 Nov;3(11):1015-7. [PubMed]
  5. Mitchell P. Biotechs hold their own in shifting industry. Nat Biotechnol. 2002 Nov;20(11):1065-6. [PubMed]
  6. Jacobs T. Is your biotech giving away the store? Nat Biotechnol. 2002 Nov;20(11):1079. [PubMed]
  7. Mitchell P. Companies struggle amid stock market gloom. Nat Biotechnol. 2002 Oct;20(10):961-2. [PubMed]
  8. Jacobs T. Biotech follows dot.com boom and bust. Nat Biotechnol. 2002 Oct;20(10):973. [PubMed]
  9. Daizadeh I, Miller D, Glowalla A, Leamer M, Nandi R, Numark CI. A general approach for determining when to patent, publish, or protect information as a trade secret. Nat Biotechnol. 2002 Oct;20(10):1053-1054. [PubMed]
  10. Dennis C. China: Stem cells rise in the East. Nature. 2002 Sep 26;419(6905):334-6. [PubMed]
  11. Gura T. Genomics. After the gold rush: gene firms reinvent themselves. Science. 2002 Sep 20;297(5589):1982-4. [PubMed]
  12. Stipp D. China's biotech is starting to bloom. Fortune. 2002 Sep 2;146(4):126-30, 132, 134. [PubMed]
  13. Berry S. Biotech meets the investors. Trends Biotechnol. 2002 Sep;20(9):370. [PubMed]
  14. Fletcher L. Pfizer-Pharmacia merger bodes ill for biotech? Nat Biotechnol. 2002 Sep; 20:857-858 [PubMed]
  15. Jacobs T. Just mad about mAbs. Nat Biotechnol. 2002 Sep; 20:869. [PubMed]
  16. Sevier ED, Dahms AS. The role of foreign worker scientists in the US biotechnology industry. Nat Biotechnol. 2002 Sep; 20:955-956. [PubMed]
  17. Littlejohn T. Sunbaked biotechnology in Australia. Nat Biotechnol. 2002 Sep; 20:873-877 [PubMed]
  18. Normile D. BIOMEDICAL SCIENCE: Can Money Turn Singapore Into a Biotech Juggernaut? Science. 2002 Aug 30;297(5586):1470-3. [PubMed]
  19. Mitchell P. Biotech stocks struggle as financial markets tumble. Nat Biotechnol. 2002 Aug; 20: 755-756. [PubMed]
  20. Ledley F. A consumer charter for genomic services. Nat Biotechnol. 2002 Aug; 20: 767. [PubMed]
  21. Jacobs T. Stock-picking warm up. Nat Biotechnol. 2002 Aug; 20: 771. [PubMed]
  22. Gold ER, Castle D, Cloutier LM, Daar AS, Smith PJ. Needed: models of biotechnology intellectual property. Trends Biotechnol. 2002 Aug;20(8):327-9. [PubMed]
  23. Dalton R. Biotech firms spurn university site. Nature. 2002 Jul 25;418(6896):355. [PubMed]
  24. Jacobs T. A summer financial makeover. Nat Biotechnol. 2002 Jul;20(7):653. [PubMed]
  25. Bouchie A. New SEC regulations could hinder biotech investment. Nat Biotechnol. 2002 Jul;20(7):639-40. [PubMed]
  26. Mitchell P. First biotech drug to treat psoriasis. Nat Biotechnol. 2002 Jul;20(7):640-1. [PubMed]
  27. Harris S. Biotechnology: the next engine of growth for Taiwan's economy?: The Taiwanese government is investing heavily in biotech infrastructure and researchers in an effort to repeat the country's success with IT technologies. EMBO Rep. 2002 Jul; 3: 598-600 [PubMed]
  28. Langmore JP. Rubicon genomics, inc. Pharmacogenomics. 2002 Jul;3(4):557-60. [PubMed]
  29. Mansfield T, Vincent MR. CuraGen Corporation. Pharmacogenomics. 2002 Jul;3(4):551-4. [PubMed]
  30. Hilgartner S. Acceptable Intellectual Property. 2002 Jun 17; J Mol Biol. 319:943-946. [PubMed]
  31. Reid B. HGS drug flop latest genomics setback.  Nat Biotechnol. 2002 Jun;20(6):533. [PubMed]
  32. Jacobs T. Sense and antisense for investors. Nat Biotechnol. 2002 Jun;20(6):543. [PubMed]
  33. Perry EL, McHugh MC. Trademarks: The "misunderstood" intellectual property. Nat Biotechnol. 2002 Jun;20(6):627-8. [PubMed]
  34. Stipp D. Can personalized drugs pay off? Fortune. 2002 May 13;145(10):168. [PubMed]
  35. Welch TJ. Bioinformatics: the role and limitations of patents. Drug Discov Today. 2002 May 6;7(11):S77-S82. [PubMed]
  36. Garabedian TE. Nontraditional publications and their effect on patentable inventions. Nat Biotechnol. 2002 Apr;20(4):401-2. [PubMed]
  37. Knight J. Software firm falls victim to shifting bioinformatics needs. Nature. 2002 Mar 28;416(6879):357. [PubMed]
  38. Razvi E. Market opportunity in computational proteomics.  Biotechniques. 2002 Mar;Suppl:54-8, 60-2. [PubMed]
  39. Cyranoski D.  Genomics firm aims to fill Asian gene gap. Nature. 2002 Mar 14;416(6877):115. [PubMed]
  40. Stemmer WP. How to publish DNA sequences with copyright protection. Nat Biotechnol. 2002 Mar;20(3):217. [PubMed]
  41. Jacobs T. Great companies, bad stocks. Nat Biotechnol. 2002 Mar;20(3):219. [PubMed]
  42. Dennis C. Venter’s departure sees Celera seek therapies. Nature 2002 Jan 31;415:461 [PubMed]
  43. Duxbury P, Mellett D.  Licence and collaboration agreements: protecting your most valuable asset. Nat Biotechnol. 2002 Jan; 20:91-92 [PubMed]
  44. Bouchie A. Shift anticipated in DNA microarray market. Nat Biotechnol 2002 Jan; 20:8 [PubMed]

last updated: 5 Feb 2003
home